Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LAB International has initiated patient enrollment for the phase II trial of its lead product, Fentanyl Taifun, a fast-acting Fentanyl formulation for the treatment of cancer pain.
Subscribe to our email newsletter
The phase II trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses. It is enrolling 112 cancer patients on maintenance opioid therapy for persistent pain.
Fentanyl is an opiate analgesic commonly used for the treatment of moderate to severe chronic pain associated with conditions such as cancer. Fentanyl Taifun incorporates a dry powder formulation of Fentanyl delivered using LAB’s proprietary Taifun dry powder inhaler.
Based on clinical data obtained to-date, Fentanyl Taifun is expected to produce pain relief within minutes from administration.
“The initiation of patient enrollment for the phase II trial is an important step in the regulatory development of Fentanyl Taifun,” said Dr Halvor Jaeger, CEO of LAB. “The enrollment of patients will continue over the next few months and results of the phase II trial will be available before year end.”